Crosser Enters The Right Arterial Lumen

NCT01205386 | Completed

• 1 other identifier: CR1055-01
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 8

Brief Summary

The purpose of this study is to determine if the CROSSER CTO Recanalization System can facilitate the successful crossing of Chronic Total Occlusions in the Central lumen of the Superficial Femoral Artery (SFA). A Chronic Total Occlusion (CTO) is defined as 100% narrowing of the artery, with no angiographically detectable antegrade blood flow, and the assessment that the lesion has been in existence for a minimum of 30 days. This study will enroll up to 100 patients at up to 8 clinical sites. The CROSSER CTO Recanalization System was cleared for commercialization by the US Food \& Drug Administration. This study also involves an imaging device called the IVUS (Intravascular Ultrasound Imaging) catheter. This device has been cleared for commercialization by the US Food and Drug Administration and will be studied for its cleared intended use. The IVUS catheter is used to generate real-time images of the artery, which will allow for evaluation of the artery after the occlusion is crossed. This is a post-market registry.

Conditions

Chronic Total Occlusion of Artery of the Extremities

Keywords

CTO; peripheral artery occlusive disease; PAOD; SFA; superficial femoral artery

Outcome Measures

Primary Outcomes (1)

• Crosser navigates through the central lumen of the artery

  Successful navigation of the CROSSER CTO Recanalization Catheter in the central lumen of the artery as confirmed by Intravascular Ultrasound (IVUS) following recanalization

  At time of procedure (day 0)

Secondary Outcomes (3)

• Technical Success - crossing the CTO into the true distal lumen

  At time of procedure (Day 0)

• Procedural Success - Technical success plus residual stenosis < 50% and improved flow

  Time of Procedure (Day 0)

• Clinical Success - freedom from limb loss and repeat revascularization

  6 month follow-up

Study Arms (1)

CROSSER

Device: 1. CROSSER System

Interventions

1. CROSSER System DEVICE

The Crosser system will be used to recanalize the chronic total occlusion in the SFA (superficial femoral artery). The IVUS (Intravascular Ultrasound Imaging) System will be used in the treated occlusion after the Crosser to generate real-time images of the artery.

Also known as: Crosser catheter, IVUS catheter

CROSSER

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with CTO who are indicated for recanalization.

You may qualify if:

• Patient must have objective evidence of lower extremity ischemia and scheduled to undergo an endovascular recanalization.
• Occluded artery must be the native superficial femoral artery.
• Patient must have a totally occlusive lesion classified angiographically as absolute (100% occlusion with no flow).
• Patient's target vessel occlusion length is ≤ 30 cm.
• Patient's reference vessel diameter is greater than or equal to 3.0mm.
• Patient must be an acceptable candidate for PTA, peripheral artery bypass surgery or peripheral artery stent implantation.
• Female patients of child bearing potential must have a negative pregnancy test within 72 hours prior to the study procedure.
• Patient or guardian must have been informed of the nature of the study, agree to its provisions, and provide written informed consent.
• Patient is ≥ 18 years of age.

You may not qualify if:

• Patient has hypersensitivity or contraindication to aspirin, heparin or radiographic contrast agents which cannot be adequately pre-medicated.
• The patient requires immediate treatment in more than one occluded vessel, in any combination of grafts or native vessels.
• Patient's occlusion is a flush occlusion initiating less than 2cm from the ostium.
• Patient has planned infrainguinal intervention scheduled within 30 days after index procedure.
• The patient is currently participating in another investigational drug or device trial that may conflict with study data collection and has not completed the entire follow-up period.
• Patient has no collateral flow distal to the occlusion.
• Patient's target occlusion has a dissection that occurred within the past 60 days caused by a guidewire attempt.
• Patient has a history of bleeding diatheses, coagulopathy or will refuse blood transfusion in cases of emergency.
• Patient suffered recent (within the past 6 months) stroke or transient ischemic neurological attack (TIA).
• Patient suffered recent (within the past 6 months) significant gastrointestinal (GI) bleeding.
• Patient has other medical illnesses (i.e., cancer or congestive heart failure) that may cause the patient to be non-compliant with the protocol, confound the data interpretation or is associated with life-expectancy less than 1 year.

Sponsors & Collaborators

• C. R. Bard: lead

Study Sites (8)

Washington Hospital Center

Washington D.C., District of Columbia, 20010, United States

Location

Iowa Methodist Medical Center

Des Moines, Iowa, 50325, United States

Location

St. John Hospital and Medical Center

Detroit, Michigan, 48236, United States

Location

Metro Health Hospital

Wyoming, Michigan, 49519, United States

Location

Mercy Heart and Vascular Center

Coon Rapids, Minnesota, 55433, United States

Location

Columbia University Medical Center

New York, New York, 10032, United States

Location

The Christ Hospital

Cincinnati, Ohio, 45243, United States

Location

Memphis Heart Clinic

Memphis, Tennessee, 38120, United States

Location

MeSH Terms

Conditions

Peripheral Arterial Occlusive Disease 1

Study Officials

• Thomas P. Davis, MD

  St. John Hospital & Medical Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 26, 2010
• First Posted: September 20, 2010
• Study Start: February 1, 2010
• Primary Completion: August 1, 2012
• Study Completion: August 1, 2012
• Last Updated: September 10, 2013

Record last verified: 2012-09

Locations

US (8)